Dengue vaccine issues in the Philippines

The Dengue virus has been difficult to control in the Philippines, and the country has been attempting to immunize its children with the new dengue vaccine Dengvaxia since January 2016.

Sanofi Pasteur, a division of French drug firm Sanofi, last month withdrew its experimental dengue vaccine Dengvaxia citing cases where the vaccine could actually increase the severity of the dengue infection and its complications in persons who received the vaccine and had never had dengue before. So after two years, the program for immunizing the kids against dengue has hit a roadblock.

Mosquito on human skin and sucking blood. Image Credit: Everything I Do / Shutterstock
Mosquito on human skin and sucking blood. Image Credit: Everything I Do / Shutterstock

Philippines Department of Health (DOH) advisory body of doctors and pharmacologists - the Formulary Executive Council (FEC) of advisers had formulated a set of recommendations at the beginning of the program. These were not accepted and the program went ahead with vaccinating 830,000 children. They had cautioned in their recommendations that the safety and cost effectiveness of the vaccine was not yet established and it should be handled carefully. There were three meetings in January where the panel had repeatedly advised caution before finally approving the purchase of the vaccine on 1st February 2016.

The letter from FEC to Garin says, “Based on the available scientific evidence presented to the Council, there is still a need to establish long-term safety, effectiveness and cost-effectiveness,” according to Reuters. They had added that there should be smaller clinical studies and pilot trials and implantation of the vaccination drive in phases to check for the effectiveness and safety of the vaccine. Instead the vaccination drive had rolled out in a single thrust across three regions at the same time. A small baseline study was indeed conducted in February March 2016 but the results were not conclusive.

The panel had also advised against purchasing in bulk to reduce its existing prices and improve upon the cost effectiveness of the vaccine. The minutes of the meeting revealed that the panel had advised that the cost of 1,000 pesos ($21.29) per dose was “not cost-effective” when the buyer was the public. These recommendations were not heeded to at the time and 3 million doses of Dengvaxia in one lot were purchased at the time to ensure that all the kids received three doses of the vaccine.

Dengue is caused by a virus carried by Aedes mosquitoes. It is a febrile illness leading to intense fever and muscle and joint pain. The infection is feared because of the complications it can cause including hemorrhagic fever leading to increased bleeding and death. This infection kills thousands each year in the tropical countries. Philippines last year has seen over 1000 deaths due to dengue and its complications.

Dr. Ananya Mandal

Written by

Dr. Ananya Mandal

Dr. Ananya Mandal is a doctor by profession, lecturer by vocation and a medical writer by passion. She specialized in Clinical Pharmacology after her bachelor's (MBBS). For her, health communication is not just writing complicated reviews for professionals but making medical knowledge understandable and available to the general public as well.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mandal, Ananya. (2018, August 23). Dengue vaccine issues in the Philippines. News-Medical. Retrieved on July 22, 2024 from

  • MLA

    Mandal, Ananya. "Dengue vaccine issues in the Philippines". News-Medical. 22 July 2024. <>.

  • Chicago

    Mandal, Ananya. "Dengue vaccine issues in the Philippines". News-Medical. (accessed July 22, 2024).

  • Harvard

    Mandal, Ananya. 2018. Dengue vaccine issues in the Philippines. News-Medical, viewed 22 July 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study reveals a promising approach to developing universal influenza vaccine